VA/DoD Hospital Meetings
The Association of VA Hematology/Oncology (AVAHO), the Federal Practitioner, PleXus Communications, and Rush University are pleased to announce a joint collaboration planned for 2017 that will focus on implementing a series of non-promotional, CME/CE accredited current/clinically relevant educational activities presented by nationally recognized faculty and developed for the specific educational needs of healthcare providers who care for active and non-active military personnel.
This complimentary 1-hour educational activity will feature a nationally recognized expert in the treatment of advanced prostate cancer. This activity is designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.
This CME meeting series is designed to meet the educational needs of medical oncologists, surgical and radiation oncologists, and other healthcare professionals involved in the treatment of veterans, their families, and active military personnel with prostate cancer.
*Flexible meeting formats that can be held at a VA/DoD Center or at an off-site location
*No fee to schedule or attend an activity
*All activities will be accredited by Rush University CME Department for physicians, nurses, pharmacists (other accreditations are available)
*We will work with your hospital's CME department and/or Medical Staff Office to obtain the necessary permissions to schedule the activity
***CLICK HERE TO REQUEST A PROGRAM***
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Current Treatment Strategies for Advanced Prostate Cancer: Sequencing Therapies and Incorporating Novel Approaches is eligible for one (1) ONCC/ILNA recertification points in the following categories: Scientific Basis for Practice; Treatment Modalities.
Rush University Medical Center designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this live activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this live activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Matthew B. Rettig, MD (Chair)
Departments of Medicine and Urology
Medical Director, Prostate Cancer Program
Institute of Urologic Oncology
Associate Director, Hematology-Oncology Fellowship Program
David Geffen School of Medicine at UCLA
Chief, Division of Hematology-Oncology
VA Greater Los Angeles Healthcare System – West LA
Judd Wendell Moul, MD
James H. Semans, M.D. Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Program: Urologic Oncology Fellowship
Urology Residency Program
Duke School of Medicine
William J. Aronson, MD
Professor, UCLA Department of Urology
Chief of Urology, UCLA/Olive View Medical Center
Director of Urologic Oncology, Wadsworth VA Medical Center
Sandy Srinivas, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Ulka Vaishampayan, MD
Chair, Division of Solid Tumor Oncology
Director of Phase I Therapeutics
Karmanos Cancer Institute
Charles Martin endowed Chair
Professor of Oncology
Wayne State University
Robert Bruce Montgomery, MD
Clinical Director of Genitourinary Medical Oncology
University of Washington
Seattle Cancer Care Alliance
Matthew Rettig, MD (Program Chair) and other prostate cancer experts are presenting a series of live 1-hour CME/CE accredited activities that are designed to help healthcare providers in VA/DoD Centers better understand best practice approaches to utilizing all the current and new therapies in advanced prostate cancer to ensure optimal patient outcomes.
1. Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
2. Outline considerations for combining and sequencing current and emerging therapies in the management of patients with advanced prostate cancer
3. Distinguish among the molecular mechanisms involved in the pathology of mCRPC as it relates to the genetic landscape of prostate cancer and personalized medicine
***CLICK HERE TO REQUEST A PROGRAM***